Cargando…
Immunogenicity of a Fractional Dose of mRNA BNT162b2 COVID-19 Vaccine for Primary Series and Booster Vaccination among Healthy Adolescents
Primary series vaccination with BNT162b2 followed by a booster 5 months later has been recommended for healthy adolescents. We aimed to describe the immunogenicity in a fractional dose of BNT162b2. Adolescents aged 12–18 years were randomized into six arms for primary series administration: 3wPZ30/3...
Autores principales: | Puthanakit, Thanyawee, Chantasrisawad, Napaporn, Yoohat, Kirana, Nantanee, Rapisa, Sophonphan, Jiratchaya, Meepuksom, Thutsanun, Sodsai, Pimpayao, Phanthanawiboon, Supranee, Jantarabenjakul, Watsamon, Hirankarn, Nattiya, Kosalaraksa, Pope |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9609361/ https://www.ncbi.nlm.nih.gov/pubmed/36298510 http://dx.doi.org/10.3390/vaccines10101646 |
Ejemplares similares
-
Heterologous Prime-boost of SARS-CoV-2 inactivated vaccine and mRNA BNT162b2 among Healthy Thai Adolescents
por: Puthanakit, Thanyawee, et al.
Publicado: (2022) -
A Randomized Clinical Trial of a Fractional Low Dose of BNT162b2 Booster in Adults Following AZD1222
por: Nantanee, Rapisa, et al.
Publicado: (2022) -
Dynamics of Neutralizing Antibody and T-Cell Responses to SARS-CoV-2 and Variants of Concern after Primary Immunization with CoronaVac and Booster with BNT162b2 or ChAdOx1 in Health Care Workers
por: Jantarabenjakul, Watsamon, et al.
Publicado: (2022) -
A randomized clinical trial of a booster dose with low versus standard dose of AZD1222 in adult after 2 doses of inactivated vaccines
por: Nanthapisal, Sira, et al.
Publicado: (2022) -
Immunogenicity of BNT162b2 in children 6 months to under 5 years of age with previous SARS-CoV-2 infection, in the era of Omicron predominance
por: Nantanee, Rapisa, et al.
Publicado: (2023)